ArticleActa paediatrica (Oslo, Norway : 1992)2026
Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.
Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore changes in body composition in adolescents with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RA) and their association with metabolic syndrome (MetS) components.
methodsThis real-world retrospective study included adolescents (12-18 years) with obesity who received multidisciplinary lifestyle-based obesity care between 2020 and 2024. GLP-1 RA therapy (liraglutide or semaglutide) was prescribed and dosed on an individualised basis. BMI and muscle-to-fat ratio (MFR) z-scores (by bioimpedance), and MetS components (glucose intolerance, hypertension, and dyslipidemia) were evaluated and compared with patients not receiving GLP-1 RA at corresponding time points. Multivariable regression analyses adjusted for sex, age, physical activity, and length of follow-up evaluated contributors for improvement in body composition.
resultsOf 67 eligible adolescents, 41 (61.2%) received GLP-1 RA therapy. The GLP-1 RA-treated group experienced greater improvements in BMI z-scores (-0.34 [-0.57, -0.07] vs. -0.07 [-0.17, 0.05], p < 0.001), and MFR z-scores (0.41 [0.12, 0.56] vs. 0.13 [0.01, 0.25], p = 0.007) compared to those without GLP-1 RA therapy. GLP-1 RA treatment duration was identified as the sole contributor to BMI and MFR z-score improvements (R
conclusionAdolescents with obesity under GLP-1 RA therapy combined with lifestyle intervention demonstrated improvements in body composition and MetS components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.